Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Milvexian setback: Phase 3 Librexia ACS trial discontinued as interim data shows futility for Bristol Myers Squibb and Johnson & Johnson Find out how the Librexia ACS trial discontinuation reshapes the future of milvexian and what it means for cardiovascular drug development today. bySoujanya RaviNovember 14, 2025